SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/30/09 -- Theravance, Inc. (NASDAQ: THRX)
announced today that Rick E Winningham, Theravance's Chief Executive
Officer, is scheduled to present at the Bank of America and Merrill Lynch
2009 Health Care Conference on Wednesday, May 13, 2009, at 10:00 a.m. EDT.
The conference will be held from March 12-14, 2009 at The Palace Hotel in
New York City.
The presentation will be webcast live and can be reached from Theravance's
web site at www.theravance.com. Listeners are encouraged to visit the site
at least 15 minutes prior to the scheduled presentation to register,
download and install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include: telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc. and the Horizon program and
Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with
GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency
toward drug discovery focused primarily on validated targets, Theravance is
pursuing a next generation strategy designed to discover superior medicines
in areas of significant unmet medical need. For more information, please
visit the company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
Theravance's presentation at the Bank of America and Merrill Lynch 2009
Health Care Conference will contain certain "forward-looking" statements as
that term is defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things, statements relating to goals, plans,
objectives and future events. Theravance intends such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Exchange Act and the Private
Securities Litigation Reform Act of 1995.
